Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 16/20 | 1.00 |
| ▸ | TTBK2 | Q6IQ55 | 16/20 | 1.00 |
| ▸ | EGFR | P00533 | 5/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.71 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.71 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24881266 | 0.87 | TTBK1 (1.00) | TTBK1TTBK2EGFRAURKB | |
| SCHEMBL30122999 | 0.84 | TTBK1 (1.00) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL24881294 | 0.84 | TTBK1 (1.00) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL26784587 | 0.84 | AURKB (1.00) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL16363320 | 0.83 | TTBK1 (0.84) | TTBK1TTBK2 | |
| SCHEMBL26784731 | 0.83 | TTBK1 (0.70) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL24882302 | 0.82 | TTBK1 (1.00) | TTBK1TTBK2EGFRAURKB | |
| SCHEMBL26785533 | 0.82 | AURKB (1.00) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL26786572 | 0.82 | EGFR (1.00) | TTBK1TTBK2EGFRAURKBINCENP | |
| SCHEMBL4741057 | 0.82 | TTBK1 (0.71) | TTBK1TTBK2EGFRAURKBINCENP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1475 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070184055-A1 | TREATMENT WITH ANTI-ERBB2 ANTIBODIES | GENENTECH, INC. | 2007-08-09 | — | — | US | claimed |
| WO-2005037259-A2 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF NEOPLASIA COMPRISING A COX-2 INHIBITOR IN COMBINATION WITH AN EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONIST | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | claimed |
| US-20040127470-A1 | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | PHARMACIA CORPORATION (US) | 2004-07-01 | — | — | US | claimed |
| US-20030086924-A1 | Treatment with anti-ErbB2 antibodies | GENENTECH, INC. | 2003-05-08 | — | — | US | claimed |
| US-20250339433-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF CANCER | JBKLAB CO.,LTD. (KR) | 2025-11-06 | — | — | US | disclosed |
| CN-119856056-A | Methods for determining the efficacy of lung cancer treatment comprising anti-PD-L1 antagonists and anti-TIGHT antagonist antibodies | 基因泰克公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-119768401-A | Bicyclic tetrahydrothiazepine derivatives | 豪夫迈·罗氏有限公司 | 2025-04-04 | — | — | CN | disclosed |
| CN-113999249-B | Methods for preparing tricyclic PI3K inhibitor compounds and methods of treating cancer using the same | 基因泰克公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119698413-A | Bicyclic tetrahydrothiazepine derivatives | 豪夫迈·罗氏有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119677843-A | Novel inhibitors of histone methyltransferase nuclear localization | 昆士兰医学研究所理事会 | 2025-03-21 | — | — | CN | disclosed |
| CN-119661711-A | CD8 binding agents and uses thereof | 豪夫迈·罗氏有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119677733-A | Bicyclic tetrahydrothiazepine derivatives | 豪夫迈·罗氏有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-6395733-B1 | ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS | PFIZER INC | 2002-05-28 | — | — | US | disclosed |
| WO-2002005842-A2 | PREVENTING AIRWAY MUCUS PRODUCTION BY ADMINISTRATION OF EGF-R ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-01-24 | — | — | WO | disclosed |
| US-20010041178-A1 | Preventing airway mucus production by administration of EGF-R antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-11-15 | — | — | US | disclosed |
| US-20010036919-A1 | Preventing airway mucus production by administration of EGF-R antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-11-01 | — | — | US | disclosed |
| US-6270747-B1 | INHIBITING HYPERSECRETION OF MUCUS IN LUNGS AND AIRWAYS BY THE ADMINISTRATION OF AN EGF-R ANTAGONIST. | THE UNIVERSITY OF CALIFORNIA | 2001-08-07 | — | — | US | disclosed |
| WO-2000010588-A9 | EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONISTS FOR TREATING HYPERSECRETION OF MUCUS IN THE LUNGS | UNIV CALIFORNIA (US) | 2000-08-10 | — | — | WO | disclosed |
| CN-1141298-A | Pyrimidine-fused heterocyclic compound anti-cancer agents | PFIZER (US) | 1997-01-29 | — | — | CN | disclosed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339433-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION, ALLEVIATION, OR TREATMENT OF CANCER | BRCA1, MATR3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TTBK1 656/4885TTBK2 214/4885EGFR 835/4885 |
| US-20040127470-A1 | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | EGFR, PTGFR, ERBB2 | TTBK1 3151/4885TTBK2 1586/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.